These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31787769)

  • 1. Experiencia con el uso de olaparib en pacientes con cáncer de ovario.
    Gallardo-Rincón D; Alamilla-García G; Montes-Servín E; Morales-Vázquez F; Cano-Blanco C; Coronel-Martínez J; Bahena-González A; Gerson-Cwilich R; Isla-Ortiz D; Toledo-Leyva A; Montes-Servín E; Michel-Tello D; Espinosa-Romero R
    Gac Med Mex; 2019; 155(6):585-589. PubMed ID: 31787769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Wu L; Zhu J; Yin R; Wu X; Lou G; Wang J; Gao Y; Kong B; Lu X; Zhou Q; Wang Y; Chen Y; Lu W; Li W; Cheng Y; Liu J; Ma X; Zhang J
    Gynecol Oncol; 2021 Jan; 160(1):175-181. PubMed ID: 33250205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
    Cao Y; Chen H; Huang Y; Hu H
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1180. PubMed ID: 32721133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
    Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
    Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 9. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    Matulonis UA; Penson RT; Domchek SM; Kaufman B; Shapira-Frommer R; Audeh MW; Kaye S; Molife LR; Gelmon KA; Robertson JD; Mann H; Ho TW; Coleman RL
    Ann Oncol; 2016 Jun; 27(6):1013-1019. PubMed ID: 26961146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel BJ; Buss MK; Nattam SR; Hurteau J; Luo W; Curtis J; Whalen C; Kohn EC; Ivy SP; Matulonis UA
    Ann Oncol; 2019 Apr; 30(4):551-557. PubMed ID: 30753272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
    Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E
    Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
    Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA
    Cancer; 2016 Jun; 122(12):1844-52. PubMed ID: 27062051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
    Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
    Hammel P; Kindler HL; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Joo S; Yoo HK; Patel N; Golan T;
    Ann Oncol; 2019 Dec; 30(12):1959-1968. PubMed ID: 31562758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.